KYMRIAH 60000000 1/1
tisagenlecleucel · INJECTION, SUSPENSION · Novartis Pharmaceuticals Corporation
KYMRIAH is a injection, suspension containing tisagenlecleucel at 60000000 1/1, taken intravenous. Manufactured by Novartis Pharmaceuticals Corporation.
Key Facts
- Brand Name
- KYMRIAH
- Generic Name
- tisagenlecleucel
- NDC Code (Product)
0078-0958- Manufacturer
- Novartis Pharmaceuticals Corporation
- Strength
- 60000000 1/1
- Dosage Form
- INJECTION, SUSPENSION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA125646
- Drug Class
- CD19-directed Chimeric Antigen Receptor [EPC]; Genetically-modified Autologous T Cells [EPC]
- Marketing Start
- 05/01/2018
Recall History
No Recall HistoryFrequently Asked Questions
What is KYMRIAH used for?
KYMRIAH contains tisagenlecleucel. It is a injection, suspension taken intravenous. Consult your doctor for specific uses.
Is KYMRIAH a controlled substance?
KYMRIAH is not classified as a controlled substance by the DEA.
What is the generic name for KYMRIAH?
The generic name for KYMRIAH is tisagenlecleucel. There are no other listed brand versions of tisagenlecleucel.
What is the NDC code for KYMRIAH 60000000 1/1?
The NDC (National Drug Code) for KYMRIAH 60000000 1/1 is 0078-0958, listed by Novartis Pharmaceuticals Corporation.
Other KYMRIAH Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)